Renal cancer (RC) represents 3% of all cancers, with a 2% annual increase in incidence
worldwide, opening the discussion about the need for screening. However, no established …

The advent of Surface-Enhanced Raman Scattering (SERS) has enabled the exploration
and detection of small molecules, particularly in biological fluids such as serum, blood …

Renal cell carcinoma (RCC) represents the sixth most frequently diagnosed cancer in men
and is asymptomatic, being detected mostly incidentally. The apparition of symptoms …

Chronic kidney disease (CKD) affects more than 10% of the global population and is
associated with significant morbidity and mortality. In most cases, this disease is developed …

Traditional tissue biopsy is limited in understanding heterogeneity and dynamic evolution of
tumors. Instead, analyzing circulating cancer markers in various body fluids, commonly …

Renal cell carcinoma (RCC) accounts for 85% of all primary renal cancers. The definitive
diagnosis of RCC relies exclusively on the subjective pathological interpretation of the …

The accuracy of renal mass biopsy to diagnose malignancy can be affected by multiple
factors. Here, we investigated the feasibility of Raman spectroscopy to distinguish malignant …

Renal cell carcinoma (RCC) remains a formidable diagnostic challenge, especially in the
context of small renal masses. The quest for non-invasive screening tools and biomarkers …

Aim Metabolites present in urine reflect the current phenotype of the cancer state. Surface-
enhanced Raman spectroscopy (SERS) can be used in urine supernatant or sediment to …

Early diagnosis based on screening is recognized as one of the most efficient ways of
mitigating cancer-associated morbidity and mortality. Therefore, reliable but cost-effective …